Form 8-K Nurix Therapeutics, Inc. For: Apr 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Nurix (NRIX) PT Raised to $23 at RBC Capital
April 11, 2024 6:28 AM EDTRBC Capital analyst Gregory Renza raised the price target on Nurix (NASDAQ: NRIX) to $23.00 (from $22.00) while maintaining a Outperform rating.
The analyst comments "The 1Q fiscal 24 EPS report recapped NRIX's recent partnership extensions that expand the company's TPD footprint in the I&I space... More
JPMorgan Takeaways on Nurix (NRIX) Q1 Earnings
April 10, 2024 12:32 PM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $30.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Nurix reported a 1Q loss per share of $0.76, with takeaways from the print being incremental to those from the companys AACR presentation, updated collaboration with SNY, and our recent discussion with mgmt. On NX-5948 (BTK degrader for B-cell malignancies), the... More
